Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cardiff Oncology (CRDF) Shares Outstanding (2016 - 2025)

Historic Shares Outstanding for Cardiff Oncology (CRDF) over the last 16 years, with Q3 2025 value amounting to $61000.0.

  • Cardiff Oncology's Shares Outstanding fell 9987.48% to $61000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $61000.0, marking a year-over-year decrease of 9987.48%. This contributed to the annual value of $66.5 million for FY2024, which is 4889.99% up from last year.
  • According to the latest figures from Q3 2025, Cardiff Oncology's Shares Outstanding is $61000.0, which was down 9987.48% from $66.5 million recorded in Q2 2025.
  • Cardiff Oncology's Shares Outstanding's 5-year high stood at $66.5 million during Q1 2025, with a 5-year trough of $61000.0 in Q3 2025.
  • Its 5-year average for Shares Outstanding is $44.8 million, with a median of $44.7 million in 2022.
  • In the last 5 years, Cardiff Oncology's Shares Outstanding soared by 24104.08% in 2021 and then plummeted by 9987.48% in 2025.
  • Quarter analysis of 5 years shows Cardiff Oncology's Shares Outstanding stood at $42.0 million in 2021, then increased by 6.47% to $44.7 million in 2022, then changed by 0.0% to $44.7 million in 2023, then surged by 48.9% to $66.5 million in 2024, then plummeted by 99.91% to $61000.0 in 2025.
  • Its Shares Outstanding was $61000.0 in Q3 2025, compared to $66.5 million in Q2 2025 and $66.5 million in Q1 2025.